1. 1) Brose MS, Nutting CM, Jarzab B, et al: DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-328.
2. 2) Schlumberger M, Tahara M, Wirth LJ, et al: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621-630.
3. 3) Kiyota N, Schlumberger M, Muro K, et al: Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 2015; 106: 1714-1721.
4. 4) Sugitani I, Miyauchi A, Sugino K, et al: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012; 36: 1247-1254.
5. 5) Bisof V, Rakusic Z, Despot M: Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made? Eur Arch Otorhinolaryngol 2015; 272: 1553-1567.